Artificial Intelligence in Assessing Gastric Intestinal Metaplasia Via the EGGIM Score
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40-75
SponsorQilu Hospital of Shandong University
About this trial
The endoscopic grading system (EGGIM) has been widely used to assess the extent of gastric intestinal metaplasia during endoscopy. Investigators developed an artificial intelligence (AI) system to automatically evaluate the extent of gastric intestinal metaplasia (GIM) and calculate the EGGIM scores in endoscopy examination. This study is a prospective, multi-center study aimed at exploring the performance and reliability of AI-EGGIM scoring.
This is a prospective study designed to validate the AI-EGGIM system in a larger cohort. The study protocol was developed based on preliminary experience from a prior investigation (NCT05464108).
Eligibility criteria
Qualifiers
patients aged 40-75 years who undergo the IEE examination
patients who voluntarily sign the informed consent form
Disqualifiers
patients with severe cardiac, cerebral, pulmonary or renal dysfunction or psychiatric disorders who cannot participate in gastroscopy
patients with previous surgical procedures on the stomach
Trial design
Treatments tested in this trial
- The diagnostic performance of AI system and endoscopists
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov